Ultime notizie per Akoya Biosciences (NASDAQ:AKYA) Azioni

Akoya Biosciences

Akoya Biosciences Inc is a life sciences technology company. It is delivering spatial biology solutions focused on transforming discovery, clinical research and diagnostics. Its PhenoCycler (formerly CODEX) and PhenoImager (formerly Phenoptics) platforms, reagents, software, and services, It offer end-to-end solutions to perform tissue analysis and spatial phenotyping across the full continuum from discovery through translational and clinical research and diagnostics.

Akoya Biosciences Inc

"Being recognized as a Transparency Project by the White House underscores the immense strategic value of the Stibnite Gold Project," said Jon Cherry, President and CEO of Perpetua Resources. "We are honored by this selection, which validates the urgency and importance of our Project for America's economic and national security. We stand ready to restore the site and bolster American mineral independence."

News

PPTA

Perpetua Resources' Stibnite Gold Project Named White House Priority For Strengthening U.S. Mineral Independence

The ONE by ONE Recycling program has collected over 101 million used contact lenses, blister packs and top foils since the program's launch in November 2016. The Biotrue Eye Care Recycling program, which launched in April 2021, has collected over 1.3 million eye drop single dose units, lens cases and lens solution caps, as well as all Biotrue-branded eye drop bottles2. Bausch + Lomb has a similar contact lens recycling program in Canada called Every Contact Counts.

BLCO

Bausch + Lomb's ONE By ONE And Biotrue Eye Care Recycling Programs Collect Over 100M Units Of Used Materials

Janney Montgomery Scott analyst Timothy Coffey upgrades Banner (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BANR#NASDAQ">BANR</a>) from Neutral to Buy.

Upgrades

Analyst Ratings

BANR

Janney Montgomery Scott Upgrades Banner to Buy

<ul>
<li>AMG to acquire a minority equity interest in Verition, a global multi-strategy investment firm with $12.6 billion in AUM</li>
<li>Verition's management will retain a substantial majority of the firm's equity and continue to lead Verition as an independent firm, in line with AMG's partnership approach</li>
<li>Partnership further diversifies AMG's business and increases its exposure to alternative strategies</li>
</ul>

AMG Acquires Minority Stake In Verition Fund Management, Expanding Alternative Investment Strategies

Creating symmetrical, same-size gold nanospheres in microgravity that could accelerate speed and accuracy of blood tests for cancer, other diseases

Redwire Expands Drug Development In Microgravity With PIL-BOX And New Cancer-Detection Experiment On ISS

Health Care

General

CTSO

CytoSorbents Received $1.7M In Cash Proceeds From The Sale Of Its 2023 And Amended 2022 Net Operating Loss And R&D Tax Credits From The Technology Business Tax Certificate Transfer Program, Sponsored By The New Jersey Economic Development Authority

MLEC

Moolec Science Sa Announced That It Has Entered Into A Business Combination Agreement With Bioceres Group Limited and Other Related Entities In An All-stock Transaction

Earnings

Earnings Beats

HBT Finl Q1 2025 Adj. EPS $0.61 Beats $0.57 Estimate, Sales $58.014M Beat $57.380M Estimate

Biotech

ARVN

Arvinas Announced That New Preclinical Combination Data For ARV-393 Will Be Presented At The American Association For Cancer Research Annual Meeting

ROCKVILLE, Md. and SUZHOU, China, April 21, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPG#NASDAQ">AAPG</a>, HKEX: 6855))), a global biopharmaceutical company engaged in discovering, developing, and commercializing therapies to address global unmet medical needs primarily for hematological malignancies, today announced that two of its proprietary novel drugs have been included in the 2025 Chinese Society of Clinical Oncology (CSCO) Guidelines. Lisaftoclax (APG-2575), the company's investigational novel oral Bcl-2 selective inhibitor, received its first recommendation in the CSCO Guidelines for the Diagnosis and Treatment of Lymphoid Malignancies. Olverembatinib, the company's novel next-generation tyrosine kinase inhibitor (TKI), received an upgraded recommendation in the CSCO Guidelines for the Diagnosis and Treatment of Leukemias in Children and Adolescent, and retained its recommendations in the CSCO Guidelines for the Diagnosis and Treatment of Hematological Malignancies.
 &nbsp;

AAPG

Ascentage Pharma's Proprietary Novel Drugs Lisaftoclax And Olverembatinib Included In 2025 Chinese Society Of Clinical Oncology Guidelines

WIIM

IVVD

Invivyd shares are trading higher after the company signed a $30 million term loan facility with Silicon Valley Bank.

UTHR

United Therapeutics Announces Series Of Presentations And Sponsored Events At ATS 2025, Highlighting Pulmonary Hypertension And Fibrosis Studies

Financing

Invivyd Signs $30M Term Loan Facility With Silicon Valley Bank

Canaccord Genuity analyst Maria Ripps maintains Netflix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>) with a Buy and raises the price target from $1150 to $1200.

Price Target

NFLX

Canaccord Genuity Maintains Buy on Netflix, Raises Price Target to $1200

Guaranty Bancshares (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GNTY#NYSE">GNTY</a>) reported quarterly earnings of $0.75 per share which beat the analyst consensus estimate of $0.71 by 5.63 percent. This is a 29.31 percent increase over earnings of $0.58 per share from the same period last year. The company reported quarterly sales of $31.76 million which beat the analyst consensus estimate of $31.10 million by 2.13 percent. This is a 10.10 percent increase over sales of $28.84 million the same period last year.

GNTY

Guaranty Bancshares Q1 2025 GAAP EPS $0.75 Beats $0.71 Estimate, Sales $31.76M Beat $31.10M Estimate

Phillips 66 Urges Shareholders To Support Board Nominees In Response To Elliott's Conflicts Of Interest

Management

IMVT

Immunovant Has Appointed Eric Venker (Currently President And COO Of Roivant) Appointed As CEO, And Tiago Girao As CFO As Pete Salzmann Retires As Immunovant CEO And Director

Interim Analysis Of DESTINY-Breast 09 Phase III Trial Showd ENHERTU Plus Ertuzumab Demonstrated Statistically Significant And Clinically Meaningful Improvement In Progression-free Survival vs Taxane, Trastuzumab And Pertuzumab As  1st-Line Treatment For Patients With Her2-positive Metastatic Breast Cancer.

Raymond James analyst Josh Beck downgrades Amazon.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) from Strong Buy to Outperform and lowers the price target from $275 to $195.

Downgrades

AMZN

Raymond James Downgrades Amazon.com to Outperform, Lowers Price Target to $195

U.S. Vice President JD Vance arrived in India on Monday for a four-day visit aimed at progressing with bilateral ties and fast-tracking a significant trade deal.
While New Delhi rolled out a cultural welcome, the visit prompted grassroots protests from the All India Kisan Sabha (All India Farmers Union), which fears that the proposed agreement could threaten the livelihoods of Indian farmers.
What Happened: Vance, joined by his wife Usha Vance, their children, and senior U.S. officials is set to conduct meetings with Prime Minister Narendra Modi and make trips to Jaipur and Agra.
On April 18, the AIKS announced its decision to stage protests on April 21 in villages and district headquarters across India with the slogan "Vance Go Back! India Is Not For Sale," with plans for effigy burnings and rallies.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">
</blockquote></div></figure>

Politics

Global

JD Vance Faces Backlash From All India Farmers Union, Who Say Bilateral Trade Talks Will Undermine Farmers, Warn 'India Is Not For Sale'

Press Releases

Akoya Reports Fourth Quarter of 2024 and Full Year Financial Results

Tikvah Management Announces Intention to Vote AGAINST Quanterix's Proposed Merger with Akoya Biosciences

Akoya Biosciences and Team SAMBAI Announce Selection of the PhenoCycler®-Fusion as the Foundational Spatial Proteomics Technology for Large-Scale Study to Address Cancer Inequities

STOCKHOLDER ALERT: The M&A Class Action Firm Continues Its Investigation Into The Merger - OPTN, SLRN, AKYA, SHYF

Kent Lake Comments on Quanterix's Value Destructive Bridge Financing for Financially Troubled Akoya

Legal

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates OPTN, SLRN, AKYA, SHYF on Behalf of Shareholders

Tikvah Management Calls on Quanterix to Explain the Egregious Terms of Convertible Notes Purchased from Akoya Biosciences

Kent Lake Files Definitive Proxy Statement and Sends Letter to Quanterix Shareholders

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BRDG, AKYA, CKPT, QTRX on Behalf of Shareholders

Penny Stocks

Small Cap

$TOCKHOLDER ALERT: The M&A Class Action Firm Continues Its Investigation Into The Merger - BRDG, AKYA, CKPT, QTRX

Comments

Akoya Biosciences

Notizie

Ultime notizie per Akoya Biosciences (NASDAQ:AKYA) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO